Patents by Inventor Matthew Angel

Matthew Angel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11466293
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: October 11, 2022
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Publication number: 20220243228
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Application
    Filed: April 12, 2022
    Publication date: August 4, 2022
    Inventors: Matthew ANGEL, Christopher ROHDE
  • Patent number: 11339410
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: May 24, 2022
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 11339409
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: May 24, 2022
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Publication number: 20220152596
    Abstract: A hydrogenolysis catalyst comprises a catalytic component that includes copper oxide, manganese oxide, and aluminum oxide, and a binder that includes a zirconium component, wherein the catalyst comprises at least about 30.0 wt % copper oxide, and the catalyst is substantially free of silicon or an oxide thereof. The hydrogenolysis catalysts are effective for converting fatty acid esters to fatty alcohols.
    Type: Application
    Filed: March 19, 2020
    Publication date: May 19, 2022
    Inventors: Jian-Ping Chen, Arunabha Kundu, Matthew Angel
  • Patent number: 11332758
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: May 17, 2022
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 11332759
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: May 17, 2022
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Publication number: 20220119839
    Abstract: Disclosed are compositions and methods comprising one or more recombinant influenza viruses. Recombinant influenza viruses with mutated polymerases and/or rearranged genomes are disclosed. Constructs comprising different influenza nucleic acid sequences are also provided. Methods of inducing protecting immunity with the recombinant influenza viruses are disclosed. Also disclosed are methods of plasmid-free production of influenza virus comprising amplicons comprising one or more of influenza genes.
    Type: Application
    Filed: May 28, 2021
    Publication date: April 21, 2022
    Inventors: Daniel R. Perez, Hongjun Chen, Yibin Cai, Lindomar Jose Pena, Matthew Angel
  • Publication number: 20220106256
    Abstract: The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Inventors: Matthew ANGEL, Franklin KOSTAS, Christopher ROHDE
  • Patent number: 11242311
    Abstract: The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: February 8, 2022
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Franklin Kostas, Christopher Rohde
  • Patent number: 11241505
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: February 8, 2022
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 11028408
    Abstract: Disclosed are compositions and methods comprising one or more recombinant influenza viruses. Recombinant influenza viruses with mutated polymerases and/or rearranged genomes are disclosed. Constructs comprising different influenza nucleic acid sequences are also provided. Methods of inducing protecting immunity with the recombinant influenza viruses are disclosed. Also disclosed are methods of plasmid-free production of influenza virus comprising amplicons comprising one or more of influenza genes.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: June 8, 2021
    Assignee: UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: Daniel R. Perez, Hongjun Chen, Yibin Cai, Lindomar Jose Pena, Matthew Angel
  • Patent number: 10982229
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: April 20, 2021
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Publication number: 20210032192
    Abstract: The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.
    Type: Application
    Filed: July 16, 2020
    Publication date: February 4, 2021
    Inventors: Matthew ANGEL, Franklin KOSTAS, Christopher ROHDE
  • Publication number: 20210024907
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Application
    Filed: March 27, 2019
    Publication date: January 28, 2021
    Inventors: Matthew ANGEL, Christopher ROHDE, Simon MOORE, Franklin KOSTAS, Jasmine HARRIS
  • Patent number: 10894092
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: January 19, 2021
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Publication number: 20210009505
    Abstract: The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells.
    Type: Application
    Filed: July 3, 2020
    Publication date: January 14, 2021
    Inventors: Matthew ANGEL, Franklin Kostas, Christopher Rohde
  • Publication number: 20210009955
    Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.
    Type: Application
    Filed: June 26, 2020
    Publication date: January 14, 2021
    Inventors: Matthew ANGEL, Christopher ROHDE
  • Patent number: 10888627
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: January 12, 2021
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Publication number: 20210000974
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Application
    Filed: September 11, 2020
    Publication date: January 7, 2021
    Inventors: Matthew ANGEL, Christopher ROHDE